Skip to Content

About Ziab

Ziab is a pioneering biotechnology company at the intersection of artificial intelligence and antibody development. Founded by a team of experts in bioinformatics, AI, and antibody research, we're on a mission to democratize access to high-quality antibodies for researchers worldwide.

Our vision is ambitious yet clear: For every protein, we will have a low-cost, high-quality antibody in our catalog.

Using proprietary AI technology and automated production systems, we're revolutionizing how antibodies are developed, validated, and produced - making them more accessible, affordable, and consistent than ever before.

Our story

Ziab was founded to address a fundamental challenge in life science research: traditional antibody development is slow, expensive, and prone to failure.

The traditional approach requires animal immunization, lengthy screening processes, and costly production methods that haven't fundamentally changed in decades. With a 60% failure rate and development cycles of 6-8 months costing upwards of $50,000 per antibody, the status quo was ripe for disruption.

Our team of experts from leading research institutions and biotech companies came together with a bold vision: leverage cutting-edge AI and automation to transform antibody development from the ground up.

Today, Ziab is making that vision a reality - delivering antibodies in days instead of months, at a fraction of the traditional cost, while maintaining the highest standards of quality and consistency.

Our approach

At the core of our technology is a proprietary AI platform that designs antibody sequences directly from target proteins, eliminating the need for animal immunization and drastically reducing development time and cost.

Our focus on single domain antibodies (sdAbs) offers unique advantages:

  • 10x smaller size enables applications like brain imaging and deep tumor penetration
  • Enhanced stability and tissue penetration
  • Faster development cycle and more consistent results
  • On-demand production without large inventory requirements

Our end-to-end automated platform handles every step of the process:

  1. AI Generation: Our algorithms design optimized antibody sequences directly from target proteins
  2. High-Throughput Validation: Advanced mass spectrometry confirms binding and specificity
  3. Automated Production: Recombinant systems produce antibodies with consistent quality
  4. Rigorous Quality Control: Continuous monitoring ensures every product meets our standards

This integrated approach allows us to offer superior products at competitive prices while dramatically expanding the range of available antibodies.



Vision


Our immediate focus is delivering high-quality research antibodies to accelerate scientific discovery. However, our vision extends beyond research applications.

The antibodies we develop have potential applications in diagnostics and therapeutics, with our growing IP portfolio creating opportunities for strategic partnerships and expanded applications.

As we scale our technology platform, we're working toward a future where any antibody can be developed rapidly, affordably, and with consistent quality - transforming not just research but potentially healthcare itself.

Join the Nanobody Revolution


Whether you're a researcher seeking better tools, a potential partner interested in our technology, or an investor who shares our vision, we invite you to connect with Ziab.


Contact us